ArticleFrontiers in endocrinology2025
Anti-Müllerian hormone and inhibin B dynamics in polycystic ovary syndrome: correlation with controlled ovarian hyperstimulation outcomes and pregnancy success.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Anti-Müllerian hormone and somatic ovarian function: a new perspective.Journal of assisted reproduction and genetics · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To investigate the dynamic changes of serum Anti-Müllerian Hormone (AMH) and Inhibin B (INHB) during controlled ovarian hyperstimulation (COH) in patients with polycystic ovarian syndrome (PCOS) and analyze their correlation with COH outcomes and pregnancy success. Methods: A total of 40 individuals diagnosed with PCOS and 40 control subjects were recruited for the study. Serum concentrations of AMH and INHB were quantified at several key time points: at the initiation of gonadotropin treatment (dGn), on the fifth day of stimulation (dGn5), on the day of hCG administration (dhCG), on the day of oocyte pick-up (dOPU), and within the follicular fluid (FF) collected on the day of oocyte retrieval, employing the ELISA method for analysis. The changes in their concentrations were explored, and their correlations with COH outcomes and pregnancy success were analyzed. Results: AMH peaks on the basal day and subsequently declines during the COH procedure. The serum AMH levels are consistently correlated with basel testosterone(T), antral follicle count(AFC), estradiol (E2) on the trigger day, retrieved oocytes, two pronuclei (2PN) fertilization, available embryos, top-quality embryos (TQE) and TQE rate (p<0.05). INHB elevates during the COH process, peaks at dHCG, and thereafter declines. Serum levels are closely associated with AFC, E2 on the trigger day, retrieved oocytes, 2PN fertilizations, available embryos and TQE rate(p<0.05). During COH, AMH and INHB in both FF and serum are interrelated. AMH levels on dOPU (β=-5.2250, P=0.0014) and INHB levels on dOPU (β=-0.1106, P<0.05) were significant negative predictors of the TQE rate. Serum INHB at dGn5 demonstrated predictive value for pregnancy outcomes (AUC = 0.71, 95% confidence interval: 0.59-0.83). Conclusion: During COH, serum AMH and INHB exhibit cyclical variations. Serum AMH and INHB especially on dOPU are closely associated with the outcomes of COH. They possess the capacity to predict the results of COH. Moreover, serum INHB (dGn5) may serve as a potential biomarker for individualized prediction of pregnancy success in PCOS patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.